Latest Health stories from Life.
This editorial reviews the recent Monitoring, Evaluation, and Results (MER) data from the PEPFAR program, offering initial insights into its programming and outcomes for FY 2025.
The U.S. Global Health Country-Level Funding Tracker presents detailed funding data categorized by program area and country, enhancing transparency in global health financing.
In a notable policy shift, President Trump has reclassified state-licensed medical marijuana as a less-dangerous drug, a change that advocates have long pursued.
Legislators in Colorado and Virginia are opposing efforts to limit the powers of prescription drug affordability boards, highlighting a significant debate over drug pricing strategies.
The U.S. military has historically recognized the dangers posed by influenza since the 1918 pandemic. Recent decisions to alter vaccine requirements could jeopardize this readiness.
As Sanofi welcomes a new CEO, the company's research priorities appear to be shifting, with a notable focus on gene therapy for deafness and developments in the biotech sector.
Federal regulators are set to unveil a new Medicare coverage pathway aimed at accelerating access to FDA-designated breakthrough medical devices, enhancing treatment options for patients.
Larry Levitt from KFF discusses the scrutiny health insurance companies are under from political figures, analyzing their impact on the healthcare system's significant issues.
In a recent shift, RFK Jr. has expressed support for vaccinations while also defending his previous secret agreements with pharmaceutical companies.
The American Medical Association is advocating for increased regulatory measures on chatbots and wellness AI, highlighting concerns about their impact on healthcare.
In a move to make healthcare more accessible, drugmakers are now offering coupons to reduce the costs associated with telehealth visits for patients seeking prescriptions.
In 2026, five technology companies have introduced AI health tools for consumers, despite lingering doubts about the accuracy of these systems.
The biotech sector is always on the lookout for the next major player. Erasca may be positioning itself as a contender, but its future remains uncertain.
Robert F. Kennedy Jr.'s recent quietness on vaccine issues appears to be a strategic move as the midterms approach, suggesting that this silence may not endure.
The increasing connections between pharmaceutical companies and telehealth providers have raised concerns among health policy experts and lawmakers.
In a notable shift, Kennedy is adjusting his approach to MAHA, stepping back from several key issues while still making an impact in health care.
A recent report highlights that a Medicare prior authorization test using AI is causing delays in care for seniors in Washington state, prompting calls for its cancellation.
The appointment of a former Imperial Brands executive to a senior position at the CDC has sparked concerns about potential tobacco industry influence within the agency.
The KFF Tracker offers current insights into the countries that have entered into bilateral Memoranda of Understanding (MOU) on global health with the United States.
This editorial outlines the current status of GLP-1 coverage in Medicare and Medicaid, highlighting CMS's initiatives aimed at improving access and reducing costs through the BALANCE model.